Written on the 6 March 2016 by The Compounding Team
Wound therapy and the treatment of scars have always been topical matters from a practical, as well as a cosmetic point of view. This article explores the effectiveness of Fatty acids, from pracaxi oil, in a topical silicone base, utilised for scar and wound therapy. The Pracasil supplied by Your Solution Compounding Pharmacy is similar to that used in the study, as prescribed by the physician and compounded to meet the specific requirements for the patient's treatment.
Sponsorship for a study was funded by the Professional Compounding Centres of America (PCCA), while medical writing assistance for the study was provided by Dr. Chantelle Rein-Smith and Robin Whitsell, of Whitsell Innovations, Inc. (Chapel Hill, USA).
The following were noted at the introduction of the study scope and presentation of the results:
- The preparation of customised treatments for individual patients represents an important therapeutic goal in the fields of dermatology and wound healing.
- Pracaxi oil, derived from the seeds of the Pentaclethra macroloba tree, indigenous to the Amazon, contains high amounts of oleic, linoleic, and behenic fatty acids which are integral to the formation and maintenance of cell membranes.
- Seven patients, ranging in age from 5 months to 72 years, with a variety of wound types, applied a compounded anhydrous silicone base containing pracaxi oil; with or without additional active ingredients.
- Satisfaction with the results was high, and the wounds or scars of all seven patients were considered "improved" or "much improved" by a dermatologist after application of the compounded base, containing pracaxi oil.
- A compounded topical anhydrous silicone base containing pracaxi oil is a potentially useful option in the management of wound and scar therapy.
A summary (below) of the study is revealing.
Wounding affects the integrity of the skin and can ultimately result in skin scarring. Current therapeutic goals of wound treatment focus on the reduction of scar formation and on severity. However, scar formation itself varies not only between individuals based on factors such as ethnicity, but also within an individual, based on the location of the wound. Therefore, the preparation of customized treatments for individual patients represents an important therapeutic goal in the fields of dermatology and wound healing. The objective of this study was to evaluate the usefulness of fatty acids found in pracaxi oil in a compounded topical anhydrous silicone base for wound and scar therapy.
Initially, 21 patients with various surgical, traumatic, or burn wounds and scars were enrolled into this case series. Patients applied a compounded topical anhydrous silicone base containing pracaxi oil with or without additional active ingredients, including pentoxifylline, caffeine, tranilast, and mupirocin. Wound/scar photographs taken before and after application of the compounded pracaxi oil topical formulation, (with/without additional ingredients), were then reviewed and adjudicated by a blinded dermatology reviewer. Improvements in wound size, coloration, and overall appearance before and after treatment were determined. Patient satisfaction was assessed after application of the compounded topical formulation, using a self-report questionnaire distributed at the time of dispensing.
A total of seven patients were considered available for analysis and were included in the study. In all seven cases, patients reported improvement in scar and wound attributes, including scar and wound size, severity, colour, and pain associated with the scar or wound after application of the compounded medicine. On average, patients rated their satisfaction with treatment highly, with a mean score of 10 on a rating scale of 1-10. Retrospective review of wound/scar photographs demonstrated clinically relevant improvements in wound attributes as assessed by a dermatologist. Six of the seven wounds examined were considered "much improved" from the baseline.
Application of a compounded anhydrous silicone base containing pracaxi oil alone, or in combination with other active substances, led to considerable improvements in wound healing and scar attributes and is a potentially useful option in the treatment of surgical, traumatic, or burn wounds and scars.
-As an example the image above is a second degree facial burn on the face of a 5-month-old infant before, and then 8 days after application of compounded base containing pracaxi oil. (Watch the video here), or select the icon.
An anecdotal and paraphrased comment from a registered nurse can perhaps best summarise a personal experience:
I want to start off by saying that I am a nurse and this is a legitimate review from a sceptical clinician. I found out about PracaSil from another nurse who works in the burn centre at my hospital in New York. There it is used to treat burn victims because of the high concentration of silicones this product contains, and as well as for pain management. I requested a script for PracaSil cream with pain medication compounded into it, which included Gabapentin 15%; the same formula used at the burn centre. I wanted this for post-op pain and scarring from a C-section with my second daughter. I had a C-section for the birth of my first child as well, and the pain afterwards was horrible. I had adverse side effects to the pain medications that I was given, and did not want to repeat that experience. In addition, I also was breast feeding and concerned about side effects on my baby. The cream arrived at my house, and I began using it immediately. I had minimal breakthrough pain and no side effects; unlike the previous time with pain pills, having tried Vicodin and OxyContin. The effects truly were remarkable. The scar virtually disappeared after 6 weeks. This included the scarring I had from my first C-section too! It is now 13 weeks post baby and there is no scar. My old scar is completely gone too, with the exception of two little skin staple hole marks.
Please contact Your Solution Compounding Pharmacy for more information about Pracasil, or visit us at 1/6 Pine Rivers Office Park, 205 Leitchs Rd. Brendale, QLD.
1. Brown BC, McKenna SP, Siddhi K, McGrouther DA, Bayat A. The hidden cost of skin scars: quality of life after skin scarring. J Plast Reconstr Aesthet Surg. 2008;61(9):10491058. doi: 10.1016/j.bjps.2008.03.020. [PubMed] [Cross Ref]
2. Bayat A, McGrouther DA, Ferguson MWJ. Skin scarring. BMJ. 2003;326(7380):8892. doi: 10.1136/bmj.326.7380.88. [PMC free article] [PubMed] [Cross Ref]
3. Brown JJ, Bayat A. Genetic susceptibility to raised dermal scarring. Br J Dermatol. 2009;161(1):818. doi: 10.1111/j.1365-2133.2009.09258.x. [PubMed] [Cross Ref]
4. Burd A, Huang L. Hypertrophic response and keloid diathesis: two very different forms of scar. Plast Reconstr Surg. 2005;116(7):150e157e. doi: 10.1097/01.prs.0000191977.51206.43. [PubMed] [Cross Ref]
5. Carvalho M. Extemporaneously compounded oral medicines in European hospital pharmacies. London: University College London; 2012. Abstract available at http://discovery.ucl.ac.uk/1396480/. Accessed 07 Nov 2014
6. Carvalho M, Taylor K, Tuleu C. Why do we need hospital pharmacy preparation? Eur J Hosp Pharm Sci Pract. 2012;19(5):467468. doi: 10.1136/ejhpharm-2012-000191. [Cross Ref]
7. Kincaid M. Options in wound care. Int J Pharm Compd. 2002;6(2):9295. [PubMed]
8. Helmke CD. Current topical treatments in wound healing, part 1. Int J Pharm Compd. 2004;8(4):269274.[PubMed]
9. dos Santos Costa MNF, Muniz MAP, Negrão CAB, et al. Characterization of Pentaclethra macroloba oil. J Therm Anal Calorim. 2014;115(3):226975.
10. Leal ICR, Júnior II, Pereira EM, et al. Pentaclethra macroloba tannins fractions active against methicillin-resistant staphylococcal and gram-negative strains showing selective toxicity. Rev Bras Farmacogn. 2011;21(6):991999. doi: 10.1590/S0102-695X2011005000132. [Cross Ref]
11. Ruthig DJ, Meckling-Gill KA. Both (n-3) and (n-6) fatty acids stimulate wound healing in the rat intestinal epithelial cell line, IEC-6. J Nutr. 1999;129(10):17911798. [PubMed]
12. Cardoso CRB, Souza MA, Ferro EAV, Favoreto S, Pena JDO. Influence of topical administration of n-3 and n-6 essential and n-9 nonessential fatty acids on the healing of cutaneous wounds. Wound Repair Regen.2004;12(2):235243. doi: 10.1111/j.1067-1927.2004.012216.x. [PubMed] [Cross Ref]
13. Banov D, Bassani AS. Permeation enhancers for topical formulations. US Patent Application Publication, Publication no. US 2012/0202882 A1; Published August 9, 2012.
14. Polonini HC, Gonçalves KM, Gomes TBB, et al. Amazon native flora oils: in vitro photoprotective activity and major fatty acids constituents. Rev Bras Farm. 2012;93(1):102108.
15. Patel MC, Patel HK, Suthar RM, Patel SR. Liposomes: as a topical drug delivery system. Int J Pharm Chem Sci. 2012;1(1):110.
16. Tanojo H, Boelsma E, Junginger HE, Ponec M, Boddé HE. In vivo human skin barrier modulation by topical application of fatty acids. Skin Pharmacol Physiol. 1998;11(2):8797. doi: 10.1159/000029813.[PubMed] [Cross Ref]
17. da Silva JO, Coppede JS, Fernandes VC, et al. Antihemorrhagic, antinucleolytic and other antiophidian properties of the aqueous extract from Pentaclethra macroloba. J Ethnopharmacol. 2005;100(12):145152. doi: 10.1016/j.jep.2005.01.063. [PubMed] [Cross Ref]
18. Teixeira RDS, Rocha PR, Polonini HC, et al. Mushroom tyrosinase inhibitory activity and major fatty acid constituents of Amazonian native flora oils. Braz Pharm Sci. 2012;48(3):399404.
19. Isaac C, Mathor MB, Bariani G, et al. Pentoxifylline modifies three-dimensional collagen lattice model contraction and expression of collagen types I and III by human fibroblasts derived from post-burn hypertrophic scars and from normal skin. Burns. 2009;35(5):701706. doi: 10.1016/j.burns.2008.11.017.[PubMed] [Cross Ref]
20. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem. 1994;116(4):892897. [PubMed]
21. Battiston B, Vasario G, Ciclamini D, Rollero L, Tos P. Reconstruction of traumatic losses of substance at the elbow. Injury. 2014;45(2):437443. doi: 10.1016/j.injury.2013.09.029. [PubMed] [Cross Ref]
22. Professional Compounding Centers of America. Technical report: efficacy of PracaSil-Plus in scar therapy treatment: a randomized, double-blind, controlled pilot trial. Houston, TX, USA. PCCA Science. 2013. Report no. 2TR0513.